Data presented at the 2026 American College of Veterinary Internal Medicine (ACVIM) Forum showed that AKS-548d and AKS-734 induced sustained anti-NGF antibody responses, functional neutralization of NGF binding to TrkA, clinically meaningful reductions in canine osteoarthritis pain, and improvements in function, with a well-tolerated safety profile..

在2026年美国兽医内科学院（ACVIM）论坛上展示的数据显示，AKS-548d和AKS-734诱导了持续的抗NGF抗体反应，功能性地中和了NGF与TrkA的结合，显著降低了犬骨关节炎疼痛并改善了功能，且安全性良好。

In a randomized exploratory head-to-head study in dogs with radiographically confirmed osteoarthritis and demonstrable osteoarthritis-related pain, AKS-548d and AKS-734 demonstrated reductions in pain, function, and orthopedic assessments that were generally consistent with those observed for bedinvetmab.

在一项针对经放射学确诊为骨关节炎且表现出明显骨关节炎相关疼痛的犬只进行的随机探索性头对头研究中，AKS-548d 和 AKS-734 在减轻疼痛、改善功能及骨科评估方面均显示出与贝丁维单抗（bedinvetmab）观察到的效果总体一致的改善。

AKS-548d and AKS-734 induced sustained endogenous anti-NGF antibody responses associated with functional neutralization of NGF-TrkA binding, the biological pathway responsible for transmitting chronic pain

AKS-548d和AKS-734诱导了持续的内源性抗神经生长因子（NGF）抗体反应，与功能性地中和NGF-TrkA结合相关，而该生物通路负责传递慢性疼痛。

In a supplemental durability cohort, AKS-548d demonstrated detectable and durable anti-NGF antibody responses through approximately Day 120 (4 months), supporting further investigation of extended dosing intervals

在一项补充性耐久性队列研究中，AKS-548d在约第120天（4个月）内显示出可检测且持久的抗NGF抗体反应，支持对延长给药间隔进行进一步研究。

AKS-548d and AKS-734 were well tolerated, with no treatment-related serious adverse events identified and no treatment-related trends in clinical pathology or body weight

AKS-548d和AKS-734耐受性良好，未发现与治疗相关的严重不良事件，也未观察到临床病理或体重方面与治疗相关的趋势。

BEVERLY, Mass.

马萨诸塞州贝弗利

,

，

July 7, 2026

2026年7月7日

/PRNewswire/ -- Akston, the Biotech Built for Pets, today announced results from a randomized head-to-head study evaluating AKS-548d and AKS-734, the company's NGF-targeting Ambifect® Fc-fusion immunotherapeutic candidates, against bedinvetmab (marketed as Librela™ by Zoetis) in dogs with radiographically confirmed osteoarthritis and demonstrable osteoarthritis-related pain..

/美通社/ -- 专为宠物打造的生物技术公司Akston今日宣布了一项随机头对头研究的结果，该研究评估了该公司靶向神经生长因子（NGF）的Ambifect® Fc融合免疫治疗候选药物AKS-548d和AKS-734，与贝丁韦单抗（由硕腾公司以Librela™品牌上市）在经放射学确诊骨关节炎并表现出明显骨关节炎相关疼痛的犬中的疗效对比。

The data, presented at the 2026 American College of Veterinary Internal Medicine (ACVIM) Forum by Andrea Delpero, Senior Manager – Pharmacology at Akston, demonstrated clinically meaningful reductions in osteoarthritis pain and improvements in function and orthopedic assessments with AKS-548d and AKS-734 that were comparable to those observed with bedinvetmab.

在2026年美国兽医内科学院（ACVIM）论坛上，Akston公司药理学高级经理Andrea Delpero展示的数据表明，AKS-548d和AKS-734在临床上显著减轻了骨关节炎疼痛，并改善了功能及骨科评估结果，其效果与bedinvetmab相当。

Both Akston candidates also induced sustained endogenous anti-NGF antibody responses associated with functional neutralization of NGF-TrkA binding, the biological pathway responsible for transmitting chronic pain. These findings support the proposed mechanism of Akston's Ambifect® platform..

Akston的两款候选药物均诱导了持续的内源性抗NGF抗体反应，这些抗体能够功能性中和NGF与TrkA的结合，而该结合是负责传递慢性疼痛的生物通路。这些发现支持了Akston公司Ambifect®平台的拟议作用机制。

Todd Zion, PhD, co-founder and CEO of Akston, commented, 'For dogs living with osteoarthritis pain, long-term treatment needs to be effective, practical, and well tolerated. Monthly anti-NGF therapy has validated this pathway as an important target for managing canine osteoarthritis pain, but chronic treatment can still create cost, compliance, and visit-burden challenges for pet owners and veterinarians.

Akston 联合创始人兼首席执行官 Todd Zion 博士评论道：“对于患有骨关节炎疼痛的犬只，长期治疗需要具备有效性、实用性和良好的耐受性。每月一次的抗神经生长因子（NGF）疗法已证实该通路是管理犬骨关节炎疼痛的重要靶点，但慢性治疗仍可能给宠物主人和兽医带来成本、依从性以及就诊负担方面的挑战。”

These data suggest our Ambifect® platform may offer a differentiated approach with the potential for durable NGF neutralization, fixed dosing independent of body weight, and fewer veterinary visits. That is exactly the kind of innovation we believe animal health needs.'.

这些数据表明，我们的Ambifect®平台可能提供一种差异化的方法，具有持久中和NGF的潜力、固定剂量且不受体重影响，并减少兽医就诊次数。这正是我们认为动物健康领域所需要的创新。

Tom Lancaster, PhD, co-founder and Chief Scientific Officer of Akston, added, 'These results are encouraging because AKS-548d and AKS-734 induced endogenous anti-NGF antibody responses associated with neutralization of NGF-TrkA binding and improvements across multiple clinically relevant osteoarthritis assessments.

Akston 联合创始人兼首席科学官 Tom Lancaster 博士补充道：“这些结果令人鼓舞，因为 AKS-548d 和 AKS-734 诱导了内源性抗 NGF 抗体反应，该反应与中和 NGF-TrkA 结合以及在多项临床相关骨关节炎评估中观察到改善有关。”

Equally important, the candidates were well tolerated, with no treatment-related serious adverse events identified and no treatment-related trends in clinical pathology or body weight. That combination of activity and tolerability supports continued development of both candidates as we move toward evaluation in client-owned dogs.'.

同样重要的是，这两种候选药物耐受性良好，未发现与治疗相关的严重不良事件，也未观察到临床病理学指标或体重出现与治疗相关的变化趋势。这种疗效与耐受性的结合支持我们继续推进这两种候选药物的研发，进而开展在客户自有犬中的评估研究。

The exploratory study in three groups of five dogs was designed to evaluate safety, immunogenicity, pharmacologic activity, and preliminary clinical observations across treatment groups. While randomized, the study was not placebo-controlled or statistically powered to evaluate efficacy versus placebo.

这项在三组各五只狗中进行的探索性研究旨在评估不同治疗组之间的安全性、免疫原性、药理活性以及初步临床观察结果。尽管该研究采用了随机设计，但并未设置安慰剂对照，也未具备足够的统计效力来评估相对于安慰剂的疗效。

Akston plans to further evaluate AKS-548d and AKS-734 in blinded, placebo-controlled studies in client-owned dogs with naturally occurring osteoarthritis..

Akston 计划在患有自然发生骨关节炎的客户饲养犬中，通过盲法、安慰剂对照研究进一步评估 AKS-548d 和 AKS-734。

Canine osteoarthritis pain

犬骨关节炎疼痛

is a chronic, progressive condition that affects mobility, comfort, and quality of life in dogs. Clinical signs can include slowing on walks, difficulty climbing stairs, reluctance to jump, and reduced activity. Nerve Growth Factor (NGF) is a key mediator of osteoarthritis pain, and neutralization of NGF is a clinically validated therapeutic approach.

是一种影响犬只行动能力、舒适度和生活质量的慢性进行性疾病。临床症状包括行走迟缓、爬楼梯困难、不愿跳跃以及活动量减少。神经生长因子（NGF）是骨关节炎疼痛的关键介导因子，而中和NGF是一种经临床验证的治疗手段。

Bedinvetmab, an approved anti-NGF monoclonal antibody for canine osteoarthritis pain, is administered by monthly subcutaneous injection based on body weight, a treatment schedule that may create compliance and cost challenges for some owners, particularly those with larger dogs..

Bedinvetmab 是一种已获批用于缓解犬骨关节炎疼痛的抗神经生长因子（NGF）单克隆抗体，需根据体重每月进行一次皮下注射；这种治疗方案可能会给部分宠物主人带来依从性和费用方面的挑战，尤其是饲养大型犬的主人。

AKS-548d and AKS-734

AKS-548d 和 AKS-734

are built on Akston's proprietary Ambifect® Fc-fusion protein platform, which leverages the patient's own immune system to generate endogenous polyclonal antibodies against a disease target. Rather than delivering an exogenous monoclonal antibody that requires frequent re-dosing, Akston's NGF-targeting Ambifect® candidates are formulated with an adjuvant and administered intramuscularly to induce sustained antibody production against NGF.

基于Akston公司专有的Ambifect® Fc融合蛋白平台构建，该平台利用患者自身的免疫系统产生针对疾病靶点的内源性多克隆抗体。与需要频繁重复给药的外源性单克隆抗体不同，Akston公司针对神经生长因子（NGF）的Ambifect®候选药物与佐剂配伍，并通过肌肉注射方式给药，以诱导针对NGF的持续抗体产生。

Because the immune response scales with the animal's size, the approach may enable fixed-dose administration rather than weight-based dosing..

由于免疫反应的强度随动物体型而变化，该方法可能实现固定剂量给药，而非基于体重的剂量调整。

Key Findings

主要发现

In the study, AKS-548d and AKS-734 produced sustained reductions in modified Canine Brief Pain Inventory (mCBPI) pain scores through Day 56, with improvements that were numerically comparable to bedinvetmab. Substantial improvements in function were also observed across treatment groups, with most dogs achieving clinically meaningful functional improvement thresholds consistent with improved mobility and activity.

在该研究中，AKS-548d 和 AKS-734 在第 56 天前持续降低了改良版犬类简明疼痛量表（mCBPI）的疼痛评分，其改善程度在数值上与 bedinvetmab 相当。各治疗组均观察到功能方面的显著改善，大多数犬只达到了具有临床意义的功能改善阈值，这与活动能力和运动能力的提升一致。

Veterinary orthopedic assessments also improved following NGF-targeted treatment, with reductions in orthopedic examination scores evident by Day 13 and generally maintained through Day 56..

针对神经生长因子（NGF）的治疗也改善了兽医骨科评估结果，骨科检查评分在第13天即出现明显下降，并通常维持至第56天。

AKS-548d and AKS-734 induced endogenous anti-NGF antibody responses that persisted through Day 56 and were associated with functional neutralization of NGF-TrkA binding in a cell-based assay. In an exploratory supplemental durability cohort, anti-NGF antibodies remained detectable through approximately Day 120 following AKS-548d immunization, supporting further investigation of extended dosing intervals with the lead candidate..

AKS-548d 和 AKS-734 诱导了内源性抗神经生长因子（NGF）抗体反应，该反应持续至第 56 天，并在细胞基检测中与 NGF-TrkA 结合的功能性中和相关。在一项探索性补充耐久性队列研究中，在 AKS-548d 免疫后约第 120 天仍可检测到抗 NGF 抗体，这支持对领先候选药物延长给药间隔进行进一步研究。

AKS-548d and AKS-734 were well tolerated. No treatment-related serious adverse events were identified. Localized injection-site reactions occurred in all treatment groups, were generally mild-to-moderate and self-limiting, and decreased in frequency following repeated dosing. No treatment-related trends were observed in hematology or clinical chemistry analyses, and body weight remained generally stable throughout the study..

AKS-548d和AKS-734耐受性良好。未发现与治疗相关的严重不良事件。所有治疗组均出现局部注射部位反应，通常为轻度至中度且具有自限性，重复给药后发生频率降低。血液学和临床化学分析中未观察到与治疗相关的趋势，研究期间体重总体保持稳定。

Potential Clinical Impact

潜在临床影响

The results suggest that Akston's NGF-targeting Ambifect® candidates have the potential to expand treatment options for canine osteoarthritis pain by combining clinically meaningful reductions in pain and improvements in function with durable immune-mediated NGF neutralization. If confirmed in client-owned dogs, an extended dosing interval could reduce the burden of monthly injections and veterinary visits, improve owner adherence to chronic osteoarthritis management, and potentially lower cumulative treatment burden over time.

研究结果表明，Akston公司针对神经生长因子（NGF）的Ambifect®候选药物有望通过结合具有临床意义的疼痛减轻和功能改善，以及持久的免疫介导NGF中和作用，扩大犬骨关节炎疼痛的治疗选择。如果在宠物犬身上得到证实，延长的给药间隔可以减轻每月注射和兽医就诊的负担，提高主人对慢性骨关节炎管理的依从性，并可能随着时间的推移降低累积治疗负担。

Fixed-dose administration, enabled by the immune system's natural scaling with animal size, could further simplify treatment logistics compared to weight-based dosing regimens..

得益于免疫系统随动物体型自然缩放的特性，固定剂量给药相比基于体重的给药方案可进一步简化治疗后勤工作。

Next Steps

下一步

Akston plans to advance AKS-548d and AKS-734 into evaluation in client-owned dogs to expand the safety and efficacy dataset, including assessment across a broader range of breeds and body sizes in dogs with naturally occurring osteoarthritis. The company will further characterize the duration of response and investigate the feasibility of a twice-a-year administration..

Akston 计划推进 AKS-548d 和 AKS-734 在客户拥有的犬只中进行评估，以扩大安全性和有效性数据集，包括在自然发生骨关节炎的犬只中跨越更广泛品种和体型范围的评估。该公司将进一步表征反应持续时间，并研究每年给药两次的可行性。

About Akston

关于Akston

Akston is a biotech company built for pets. Using its proprietary Fc-fusion protein platform, Akston develops immuno-enhancing and targeted protein treatments that aim to reduce treatment frequency while enhancing efficacy. Backed by a vertically integrated structure and state-of-the-art biologics facilities, Akston accelerates development from discovery to commercial manufacturing — ensuring innovation reaches veterinarians and the pets we love faster and more efficiently.

Akston 是一家专为宠物打造的生物技术公司。凭借其专有的 Fc 融合蛋白平台，Akston 开发出免疫增强型和靶向性蛋白质疗法，旨在减少治疗频率并提高疗效。依托垂直整合的架构和先进的生物制剂设施，Akston 加速从发现到商业化生产的全过程，确保创新成果更快、更高效地惠及兽医及我们珍爱的宠物。

Learn more at .

了解更多，请访问。

www.akston.com

www.akston.com

.

。

AKS-548d and AKS-734 are investigational therapeutics and are not approved for commercial use.

AKS-548d 和 AKS-734 是研究性治疗药物，尚未获批用于商业用途。

SOURCE Akston Biosciences

来源：Akston Biosciences

21

二十一

%

百分比

more press release views with

更多新闻稿浏览量，通过

Request a Demo

请求演示